Zhejiang Huahai Pharmaceutical Co Ltd (600521.SS) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE000001DL5

Price
16.28 CNY
Market cap
24.38 bn CNY
P/E (2025)
91.50
P/S (2025)
2.84
Dividend yield
0.61 %
Net margin
3.10 %
Return on equity (ROE)
2.82 %
Return on assets (ROA)
1.24 %

Zhejiang Huahai Pharmaceutical Co Ltd financials

Fiscal year20242025
Revenue9.55 bn CNY8.59 bn CNY
Gross profit5.81 bn CNY5.17 bn CNY
Operating income1.47 bn CNY833.51 m CNY
EBIT1.62 bn CNY677.48 m CNY
Net income1.12 bn CNY266.40 m CNY
Diluted EPS – continuing operations0.77 CNY0.18 CNY

Full history since 2000, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Zhejiang Huahai Pharmaceutical Co Ltd

Zhejiang Huahai Pharmaceutical Co., Ltd. engaged in the research, development, production, and sales of generic drugs, biologics, drugs, and specialty active pharmaceutical ingredients in multiple dosage forms in China and internationally. The company offers central neurological, cardiovascular, anti-viral, and other products, as well as APIs and intermediates. It also provides packaging components, such as polyethylene bottles and polypropylene caps for pharmaceuticals. In addition, the company offers contract manufacturing and other services, as well as import and export trade services. Zhejiang Huahai Pharmaceutical Co., Ltd. was founded in 1989 and is headquartered in Linhai, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 23.10.2026. Details in the risk notice.